Amplistar files patents for cancer antibody markers:
This article was originally published in Clinica
Executive Summary
US biotech firm Amplistar has filed seven provisional patent applications in the US that focus on using specific antibodies for the early detection of colon, lung and prostate cancers. The Winston-Salem, North Carolina company claims that cancer antibodies can be detected in blood earlier than the tumour marker proteins that are identified by current cancer tests. Amplistar expects to file provisional patent applications covering 10 additional new antibody targets for several cancers by the end of the year.